Editorials

Transitions A.A.M. Bookman ........................................... 1
Send Us Your Best E. Silverman .................................. 3
Evaluating the Real-world Benefits and Risks of Anti-Tumor Necrosis Factor Therapies A. Low, K. Hyrich .... 4
Rhubarb and Reliability — A Jane Austen View of Systemic Lupus Erythematosus D.A. Isenberg .............. 7

Review

The Risky Business of Studying Prognosis L.S.H. Lim, B.M. Feldman .................................................. 9

Articles

Hospitalizations of Patients Treated with Anti-TNF-α Agents — A Retrospective Cohort Analysis
D. Zisman, A. Haddad, S. Hashoul, et al ........................................... 16
Reliability and Longitudinal Validity of Computer-assisted Methods for Measuring Joint Damage Progression in Subjects with RA
M.Q.W. Poh, M. Lassere, P. Bird, J. Edmonds .................................. 23
HCQ Use is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in SLE A. Broder, C. Putterman .................................................. 30
Development and Assessment of Users’ Satisfaction with the SLEDAI 2000 Responder Index-50 Website
Longterm Effects of Endothelin Receptor Antagonism on Microvascular Damage Evaluated by Niflodium Capillaroscopic Analysis in SSc M. Cutoio, G. Zamponga, L. Vremis, V. Smith, C. Pizzorni, A. Sulli .................................................. 40
Is Vasculopathy Associated with SSc More Severe in Men? S.T. Panopoulos, V-K. Bounia, P.P. Sifakis .................. 46
Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early SSc with Diffuse Skin Involvement V. Smith, Y. Piette, J.T. Van Praet, S. Decuman, E. Deschepper, D. Elewaut, F. De Keyser .......... 52
Quantitative Radiographic Features of Early Knee OA: Development Over 5 Years and Relationship with Symptoms in the CHECK Cohort M.B. Kinds, A.C.A. Marijnissen, J.W.J. Bijlsma, M. Boers, F.P.J.G. Lafeber, P.M.J. Welsing .................................................. 58

Consensus Statements for the Use of Administrative Health Data in Rheumatic Disease Research and Surveillance S. Bernatsky, L. Lix, S. O’Donnell, D. Lacaille, and the CANRAD Network .................................. 66

Pediatric Rheumatology

Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in JIA: 1-year Followup Data from the Italian Registry
M.E. Zannin, C. Biolo, V.M. Gerloni, et al ....................................... 74
MTX and Injectable TNF-α Inhibitor Adherence and Persistence in Children with Rheumatic Diseases S. Ringold, S. Grant, C. Girdish, C.A. Wallace, S.D. Sullivan .............................................................. 80

Images in Rheumatology

Polyarteritis Nodosa A.P. Diamantopoulos, P. Pettersen ................................................................. 87

Correspondence

The Optimal Tool for Assessment of Organ Damage in APS M. Barbaia, D. Erkan ........................................... 89
Reply P.G. Viachoyiannopoulos .................................................. 90
Right Ventricular Function in Systemic Sclerosis-associated PAH M. Koestenberger, W. Ravekes ....................................... 90
Reply S.C. Mathai, P.M. Hassoun .................................................. 91
Is “F Fluorodeoxyglucose PET Useful to Assess Activity of Myositis? N. Pipitone, A. Versari, C. Salvarani .................................................. 91
Reply T. Owada, R. Maezawa, K. Kurasawa ........................................... 92
Low Prevalence of Anti-DFS70/LEDGF Antibodies in Patients with Dermatomyositis and Other Systemic Autoimmune Rheumatic Diseases Y. Muro, K. Sugiyura, R. Nakashima, T. Mimori, M. Akiyama .................................................. 92
Reply M. Mahler ................................................................. 94
Myopericarditis and Giant Cell Arteritis in the Elderly J.R. Nair, R. Karumanchery .................................................. 95
Reply B. Granel, A. Daumas, P. Rossi, A. Jacquier .................................................. 96

Contents continued opposite inside back cover . . .
Letters

HLA-B*5801 Should Be Used to Screen for Risk of Stevens-Johnson Syndrome in Family Members of Han Chinese Patients Commencing Allopurinol Therapy

Skin Perfusion of Fingers Shows a Negative Correlation with Capillaroscopic Damage in Patients with SSc
E. Rosato, A. Giovannetti, S. Pisarri, F. Salsano ........... 98

Hepatitis E: Are Rheumatic Patients at Risk?
C.H. Roux, R. Anty, S. Patouraux, L. Euller-Ziegler .... 99

Refractory Relapsing Polychondritis Treated with Serial Success with IL-6R Blockade
Z.S. Wallace, J.H. Stone .................................. 100

Renal Lymphoma: Unusual Lymphoproliferative Manifestation of Sjögren’s Syndrome
S. Patel, N. Kramer, A.J. Cohen, E.D. Rosenstein ........ 102

Achilles Tendinopathy After Treatment with Ophthalmic Moxifloxacin
H. Gladue, M.J. Kaplan .................................. 104

Eosinophilic Fascitis in Siblings
C. Sullivan, R. Coughlan .................................. 105

Book Review

Scleroderma. From Pathogenesis to Comprehensive Management ............................................. 106

Correction

Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry

Meetings in Rheumatology .................................. x